Treatment of persistent fetal circulation syndrome of the newborn. Comparison of different doses of tolazoline.
The effects of two doses of tolazoline have been compared in 2 groups of newborns suffering from the persistent fetal circulation syndrome. The effects on PaO2 and AaDO2 were similar in the 2 groups who received either a bolus of 1 or 0.5 mg X kg-1 tolazoline, followed by a continuous infusion of 1 or 0.5 mg X kg-1 X h-1. The observed changes did not differ significantly from those previously observed in babies treated with 2 mg X kg-1. A rise in PaO2 and a reduction in AaDO2 were usually observed shortly after the bolus injection and at plasma levels between 1.5 and 4 micrograms X ml X -1. A progressive rise in plasma level over time occurred after 1 mg X kg-1 (and in the previous study of 2 mg) but not with 0.5 g/kg tolazoline. The elimination half-life of tolazoline in 6 patients was 5 to 13 h. The data suggest that continuous infusion of tolazoline is not necessarily required and that the dose of 0.5 mg/kg is more appropriate and safer than the higher doses usually proposed.
D001794:Blood Pressure / Q000187:drug effects; D002245:Carbon Dioxide / Q000097:blood; D004334:Drug Administration Schedule; D006207:Half-Life; D006801:Humans; D007231:Infant, Newborn; D007700:Kinetics; D010100:Oxygen / Q000097:blood; D010547:Persistent Fetal Circulation Syndrome / Q000097:blood / Q000188:drug therapy*; D011659:Pulmonary Gas Exchange / Q000187:drug effects; D014043:Tolazoline / Q000008:administration & dosage* / Q000097:blood / Q000627:therapeutic use
D002245:Carbon Dioxide; D014043:Tolazoline; D010100:Oxygen